Progyny Q4 2025 Earnings Preview: Revenue Slowdown Anticipated - News and Statistics

NodeGuardian · 2026-03-14T03:40:06+00:00

Progyny is set to report Q4 2025 earnings with expected revenue growth slowing to 3.3%. The company has a history of missing revenue estimates, unlike competitors CVS Health and Cigna, and its stock has recently underperformed, dropping 16.3%.

NodeGuardian

2026-03-14 03:40:06

Geração de resumo em curso

Progyny is preparing to report its Q4 2025 earnings, with analysts anticipating a slowdown in revenue growth to 3.3% year-on-year, compared to 10.6% in the prior year’s same quarter. The company has previously missed Wall Street’s revenue estimates multiple times in the last two years, contrasting with competitors like CVS Health and Cigna who recently exceeded expectations. Progyny’s stock has underperformed the sector, dropping 16.3% over the last month, and its current share price is significantly below the average analyst price target.

Esta página pode conter conteúdos de terceiros, que são fornecidos apenas para fins informativos (sem representações/garantias) e não devem ser considerados como uma aprovação dos seus pontos de vista pela Gate, nem como aconselhamento financeiro ou profissional. Consulte a Declaração de exoneração de responsabilidade para obter mais informações.